Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

Key Points

• Replimune reported a quarterly loss of $0.72 per share, missing analysts’ consensus estimate of a $0.69 loss. Shares fell 1.4% to $14.97 during Friday trading.
• The company received FDA accelerated approval for TUDRIQEV™ (RP1) combined with nivolumab for advanced melanoma and expects to launch within 60 days, creating a potential commercial revenue stream.
• Replimune raised $150 million to support the product launch and required confirmatory trial, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $11.86.

Replimune Group (NASDAQ:REPL - Get Free Report) released its earnings results on Friday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03), Zacks reports.

Replimune Group Trading Down 1.4%

Shares of NASDAQ REPL traded down $0.22 during midday trading on Friday, reaching $14.97. 2,398,241 shares of the stock were exchanged, compared to its average volume of 8,223,322. The stock has a 50 day moving average price of $10.66 and a 200-day moving average price of $7.79. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. Replimune Group has a 52-week low of $1.50 and a 52-week high of $15.70.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of Replimune Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company's stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 81,868 shares of company stock worth $1,017,068 in the last quarter. 5.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Entropy Technologies LP acquired a new stake in Replimune Group in the 4th quarter valued at approximately $102,000. Commonwealth Equity Services LLC acquired a new stake in shares of Replimune Group in the fourth quarter worth $150,000. Inceptionr LLC acquired a new position in Replimune Group in the 4th quarter valued at approximately $172,000. HighTower Advisors LLC raised its stake in shares of Replimune Group by 24.8% during the 4th quarter. HighTower Advisors LLC now owns 20,123 shares of the company's stock worth $196,000 after purchasing an additional 3,994 shares in the last quarter. Finally, Scientech Research LLC acquired a new stake in shares of Replimune Group in the third quarter worth about $102,000. Institutional investors own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on REPL. Wolfe Research upgraded shares of Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. Weiss Ratings cut shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Replimune Group in a report on Wednesday. Finally, Wall Street Zen raised shares of Replimune Group from a "strong sell" rating to a "sell" rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.86.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: FDA approval creates a commercial opportunity: Replimune announced that TUDRIQEV™ (RP1) in combination with nivolumab received FDA accelerated approval for advanced melanoma. The company expects to launch the treatment within 60 days, potentially allowing it to begin generating commercial revenue and validating its oncolytic-immunotherapy platform. Replimune fiscal first-quarter 2027 results and corporate update
• Positive Sentiment: Financing supports the launch: A recently completed $150 million financing extends Replimune’s cash runway and is intended to fund the commercial rollout and confirmatory trial required under the accelerated-approval pathway. The added liquidity reduces near-term funding concerns, though the offering may dilute existing shareholders. Replimune corporate update
• Positive Sentiment: Commercial leadership added: Michelle DiNapoli was appointed chief commercial officer, strengthening the company’s preparations for its first product launch.
• Neutral Sentiment: Insider sales were attributed to taxes: The CEO, CFO, CAO and another insider sold shares totaling approximately $906,000. SEC filings indicate the transactions covered tax withholding tied to vested equity awards, and the executives retained significant holdings, limiting the negative signal.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Replimune reported a fiscal first-quarter loss of $0.72 per share versus the consensus estimate of a $0.69 loss. As a commercial-stage biotechnology company, it remains unprofitable and is expected to post a substantial full-year loss.
• Negative Sentiment: Securities litigation remains an overhang: Multiple law firms are promoting a class action covering investors who bought REPL shares from October 20, 2025, through April 10, 2026. The lawsuit alleges misleading statements about RP1 and FDA study-design issues; the allegations have not been proven. The lead-plaintiff deadline is October 5, 2026. Replimune securities lawsuit deadline alert

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source